Newron Pharmaceuticals - Edison Group

Newron Pharmaceuticals (SIX: NWRN)

Currency in CHF

Last close As at 06/12/2023

CHF4.65

▲ 0.09 (1.97%)

Market capitalisation

CHF83m

Overview
Price performance
Financials
Research
Sector insights
Thematics

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase II/III trial programme targeting schizophrenia.

Xadago is marketed as an add-on to levodopa therapy in PD. It is currently sold in Europe, Japan, the United States and other territories. Generic manufacturers have notified the FDA of their intention to file generic Xadago products. Newron is contesting these filings. Xadago is currently patent protected until at least 2027.

Latest Insights

View More

Healthcare |
Update

11.10.23

Newron Pharmaceuticals — Positive readout highlights evenamide potential

Healthcare |
Update

07.08.23

Newron Pharmaceuticals — Crucial upcoming datasets for evenamide

Healthcare |
Flash note

16.05.23

Newron Pharmaceuticals — Encouraging efficacy data from evenamide trial

Healthcare |
Flash note

20.03.23

Newron Pharmaceuticals — Positive top-line data to support clinical progress

Sector

Healthcare

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Analyst

Associate analyst

Key Management

Marco Caremi

Executive VP of Business Development
Stefan Weber

CEO

Balance Sheet

Forecast net cash (€m)

21.8

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(8.1)	(15.5)	244.4
Relative	(11.7)	(16.0)	247.8
52 week high/low	CHF8.0/CHF1.3

Financials

Newron is developing evenamide as an add-on therapy for poorly managed and treatment-resistant schizophrenia (TRS). A potentially pivotal Phase III trial (study 008A) in patients with schizophrenia who are taking antipsychotics but not classified as having TRS is underway; readouts are expected in Q423 or Q124. In the Phase II trial (study 014/015) for patients with TRS, evenamide has demonstrated both safety and efficacy in readouts to date. In October 2023, encouraging interim readouts were reported corresponding to the six-month timepoint for the full 161-patient cohort in extension study 015; full one-year data are expected in Q124. Newron intends to begin an additional, potentially pivotal, multinational Phase III study (study 003) in TRS patients (expected to start in Q124). In its H123 results, Newron recorded total revenue of €5.5m for the period, nearly double H122’s revenue of €2.8m, primarily driven by higher royalty income for Xadago.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2021A	5.8	(11.4)	(14.1)	(79.23)	N/A	N/A
2022A	6.1	(12.6)	(17.0)	(95.34)	N/A	N/A
2023E	8.9	(11.7)	(14.6)	(81.90)	N/A	N/A
2024E	6.8	(19.1)	(22.3)	(124.77)	N/A	N/A

Research

QuickView

Healthcare

01.11.21

Newron Pharmaceuticals — Pivotal progress on schizophrenia therapy

Update

Healthcare

27.09.21

Newron Pharmaceuticals — Evenamide validation underway

Healthcare

Flash note

Newron Pharmaceuticals — Evenamide potential expanding in schizophrenia

Update

Healthcare

08.09.21

Newron Pharmaceuticals — Evenamide Phase III at 30mg twice daily dose

Update

Healthcare

18.05.21

Newron Pharmaceuticals — Long-term generic challenge to Xadago

Update

Healthcare

07.04.21

Newron Pharmaceuticals — Gate not yet open to Phase III

Update

Healthcare

29.03.21

Newron Pharmaceuticals — Dyskinesia deal delivered

Update

Healthcare

25.01.21

Newron Pharmaceuticals — Evenamide Phase II completes recruitment

QuickView

Healthcare

17.11.20

Newron Pharmaceuticals — Schizophrenia development adds value

edison tv

Healthcare

09.11.20

Newron Pharmaceuticals – EKF interview

Update

Healthcare

22.09.20

Newron Pharmaceuticals — Evenamide trial progressing well

Update

Healthcare

26.08.20

Newron Pharmaceuticals — Evenamide safety trial underway

Update

Healthcare

22.05.20

Newron Pharmaceuticals — Evenamide focus, Supernus to sell Xadago in US

Flash note

Healthcare

05.05.20

Newron Pharmaceuticals — Sarizotan fails to shine

Update

Healthcare

26.03.20

Newron Pharmaceuticals — Seeing STARS

Update

Healthcare

04.10.19

Newron Pharmaceuticals — Xadago slows, Evenamide lags but STARS ahead

Update

Healthcare

31.05.19

Newron Pharmaceuticals — Evenamide down but not out

Outlook

Healthcare

14.03.19

Newron Pharmaceuticals — Moving towards R&D inflection points

Update

Healthcare

11.10.18

Newron Pharmaceuticals — Next up – R&D day

Update

Healthcare

04.04.18

Newron Pharmaceuticals — 2018 focus on the CNS pipeline

Flash note

Healthcare

22.03.17

Newron Pharmaceuticals — Xadago receives FDA approval in PD

Update

Healthcare

13.03.17

Newron Pharmaceuticals — Marching into 2017

Outlook

Healthcare

02.09.16

Newron Pharmaceuticals — Update 2 September 2016

Flash note

Healthcare

31.03.16

Newron Pharmaceuticals — Update 31 March 2016

Flash note

Healthcare

18.03.16

Newron Pharmaceuticals — Update 17 March 2016

Update

Healthcare

15.03.16

Newron Pharmaceuticals — Update 14 March 2016

Update

Healthcare

21.12.15

Newron Pharmaceuticals — Update 20 December 2015

Further insights

insight

Healthcare

20.11.23

Newron Pharmaceuticals: EKF 2023 QuickView

insight

Healthcare

16.11.22

Deutsches Eigenkapitalforum (EKF) 2022 healthcare

insight

Consumer

26.07.22

Deutsches Eigenkapitalforum (EKF) 2022

Analyst of the week

Soo Romanoff

Managing Director - Head of Content, Healthcare

sromanoff@edisongroup.com 020 3077 5700

Read latest

thematic

Healthcare

06.01.23

Outlook for 2023: Biotechs remain central to novel drug development

Cancer cells

thematic

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

cell DNA double helix

thematic

Healthcare

20.12.22

Cell and gene therapies

thematic

Healthcare

28.11.22

Drug delivery platforms

thematic

Healthcare

07.11.22

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

01.11.22

Neuroscience comeback

thematic

Consumer

05.10.22

IPO apocalypse

thematic

Healthcare

03.10.22

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

10.08.22

ESG, moving beyond the box tick

thematic

Healthcare

01.07.22

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

26.04.22

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

10.11.21

Artificial intelligence in drug discovery

thematic

Healthcare

27.07.21

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Healthcare

01.02.21

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Healthcare

30.10.19

Edison Exhibits- antibiotic development

thematic

Healthcare

17.07.19

The next wave in AMD

thematic

Healthcare

18.06.19

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

10.06.19

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

22.05.19

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

08.04.19

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Healthcare

04.03.19

Drug pricing – Market access and reimbursement

thematic

Healthcare

29.01.19

The diagnostics sector

thematic

Healthcare

21.06.17

ASCO 2017

thematic

Consumer

11.11.14

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

05.03.14

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Energy & Resources

04.03.14

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

01.03.13

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

07.12.12

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

30.08.12

Edison healthcare quarterly: Crisis? What crisis?

thematic

Healthcare

28.05.12

Edison healthcare quarterly: How to please some of the people some of the time